Sanuwave Health Inc. (SNWV) shares ended the last trading session 9.1% higher at $40.82. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.2% loss over the past four weeks.The sharp rise in SNWV shares can be attributed to the company reporting record preliminary Q3 2025 revenues of $11.4–$11.6 million, reflecting a 22–24% year-over-year and 12–14% sequential increase. The results marked the highest quarterly reven ...

U.S. stock futures fell on Tuesday following Monday’s mixed moves. Futures of major benchmark indices were lower.The Advanced Micro Devices Inc. (NASDAQ:AMD) deal with OpenAI fueled the rally in AI-linked stocks on Monday, which has been powering Wall Street’s bull run this year.Meanwhile, President Donald Trump indicated willingness to work with the Democrats on healthcare and other policies, but only after they reopened the government, which is in its seventh day of a shutdown that began on Oct. 1. The U. ...

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects McCormick & Company Inc. (NYSE:MKC) to post quarterly earnings at 81 cents per share on revenue of $1.71 billion before the opening bell, according to data from Benzinga Pro. McCormick shares gained 1.3% to $69.19 in after-hours trading.SANUWAVE Health Inc. (NASDAQ:SNWV) issued preliminary third-quarter revenue results below estimates and also cut its FY25 r ...

Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased between 22% and 24% vs Q3 2024 and between 12% and 14% sequentially vs the prior quarter First nine months of 2025 revenue increased 39-40% vs first nine months of 2024. EDEN PRAIRIE, Minn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a le ...

The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current market environment may also lie in its non-cyclical nature, thanks to resilient demand that is more related to health needs and demographics than to external economic conditions. However, finding healthcare names poised for major growth may be difficult, considering that many of the largest legacy firms in the spac ...

Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have an interest rate of SOFR +350bp The Company drew approximately $1 million from the revolver at commencement, resulting in total outstanding debt under the new facility of approximately $24 million. Company announces the repayment in full of NH Expansion debt facility with new credit facility from J.P. Morgan ...

Core Insights - SANUWAVE Health, Inc. is a leader in regenerative medicine, focusing on non-invasive, high-energy acoustic pressure shockwave technology for applications in wound care and orthopedics [1] - The company's financial metrics, particularly ROIC and WACC, indicate strong efficiency and financial health [1] Financial Performance - SANUWAVE's ROIC is 54.33%, significantly higher than its WACC of 16.34%, resulting in a ROIC to WACC ratio of 3.32, demonstrating robust returns above its cost of capital [2] - In contrast, Rafarma Pharmaceuticals, Inc. and Pressure BioSciences, Inc. have lower ROIC to WACC ratios of 0.54 and 0.63, respectively, while GulfSlope Energy, Inc. has a negative ROIC, highlighting SANUWAVE's superior performance [3]

Group 1 - The US overall wound care market is projected to reach a value of $7.4 billion by 2025, indicating significant growth potential in this sector [1] - The analysis highlights the opportunity within the wound care market, particularly focusing on companies like Sanara MedTech, which are undercovered and may present asymmetric investment opportunities [1] Group 2 - The article emphasizes the importance of thorough research and analysis in identifying small to mid-cap companies that are often overlooked by other investors, aiming for market-beating returns [1] - The author has a background in electrical engineering and currently works in automotive battery R&D, which adds a technical perspective to the investment analysis [1]

Company Overview - SANUWAVE Health, Inc. focuses on developing and commercializing non-invasive, biological response-activating devices for the healthcare sector, primarily targeting chronic conditions and wound healing [1] Financial Performance - SANUWAVE has a Return on Invested Capital (ROIC) of 54.33%, significantly higher than its Weighted Average Cost of Capital (WACC) of 15.85%, resulting in a ROIC to WACC ratio of 3.43, indicating substantial returns on invested capital [2][6] - TSS, Inc. has the second-highest ROIC to WACC ratio of 2.02 among peers, with a ROIC of 23.21% and a WACC of 11.51%, reflecting efficient capital utilization [3][6] - Pressure BioSciences, Inc. has a ROIC of 42.55% but a high WACC of 67.83%, leading to a ROIC to WACC ratio of 0.63, indicating less effective capital utilization [4] - Rafarma Pharmaceuticals, Inc. shows a ROIC of 3.03% and a WACC of 5.49%, resulting in a ROIC to WACC ratio of 0.55, suggesting inefficient capital utilization [4] - GulfSlope Energy, Inc. has a concerning ROIC of -1932.28% against a WACC of 5.71%, resulting in a negative ratio of -338.65, indicating it is not covering its cost of capital [5] - Aspen Group, Inc. also presents a negative ROIC of -4.51% and a WACC of 17.88%, leading to a ratio of -0.25, which is a red flag for potential investors [5]

Financial Data and Key Metrics Changes - The company reported a total of 8,569,338 shares of common stock issued and outstanding as of the record date [7] - A quorum was established with more than half of the outstanding shares present at the meeting [8] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided in the meeting records Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The meeting included proposals for the election of directors and the ratification of the independent registered public accounting firm, indicating ongoing governance and compliance efforts [10][11] - The company proposed an amendment to increase the number of shares authorized for issuance under the equity incentive plan, suggesting a focus on incentivizing management and employees [11] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The meeting was conducted virtually, allowing shareholders to vote online [4] - The results of the voting will be disclosed in a current report on Form 8-K within four business days [13] Q&A Session All Questions and Answers Question: Were there any shareholder questions during the meeting? - No questions were submitted by shareholders during the meeting [14]